Valneva cuts jobs and lowers outlook as its Lyme disease deal with Pfizer hangs in balance
For a company dedicated to protecting people from some of the world’s most persistent diseases, Valneva is in the middle of its own difficult fight. The French biopharmaceutical firm is cutting up to 15% of its global workforce, trimming spending aggressively and rethinking its core business, all while placing its biggest hopes on a Lyme disease vaccine co-developed with Pfizer that still has a long road ahead.
A steep revenue drop forces serious cutbacks
Valneva’s first-quarter 2026 results painted a challenging picture. Total revenues fell to 30.9 million euros for the three months ended March 31, down nearly 40% from 49.2 million euros reported during the same period a year ago. The company pointed to several contributing factors behind the decline, including a deliberate shift away from distributing third-party vaccines, changes in military delivery schedules and the early signs of a broader slowdown in travel vaccine demand tied to geopolitical tensions around the world.
To manage the financial strain, Valneva launched a restructuring plan that includes reducing its global headcount by between 1) 10% and 2) 15%. The company entered 2026 with 674 employees spread across 1. Austria, 2. Canada, 3. France, 4. Sweden, 5. the United Kingdom and 6. the United States.
The broader restructuring is expected to reduce overall operating costs by between 25% and 35% compared to 2025 levels, with the bulk of savings expected to come from research and development spending. The company also revised its full-year 2026 product sales guidance downward to between 135 million euros and 150 million euros, from a prior range of 145 million euros to 160 million euros.
A Lyme vaccine that could reshape everything
Despite the turbulence, Valneva’s Pfizer-partnered Lyme disease vaccine remains the company’s most closely watched asset. The vaccine targets the most common disease-causing strains on both sides of the Atlantic and demonstrated efficacy above 70% in a Phase 3 trial involving participants aged five and older, with no significant safety concerns identified at the time of analysis.
While the trial did not meet its first pre-specified statistical criterion, the second was met, and Pfizer has expressed confidence in the vaccine’s prospects, with regulatory submissions now in planning.
No vaccine currently exists to protect humans against Lyme disease, and the annual burden is growing. Roughly 90 million people across North America and more than 200 million in Europe live in high-risk areas, while approximately 500,000 cases are reported in the United States each year, a figure widely believed to be significantly underreported. The vaccine would be the only candidate of its kind to reach this stage of development in nearly 30 years.
Chikungunya progress and a Shigella decision coming soon
Valneva’s chikungunya vaccine is gaining ground in emerging markets, particularly through a major pilot vaccination campaign underway in Brazil targeting adults between 18 and 59 years old. More than 30,000 people have already received the shot, and the program aims to exceed 100,000 total vaccinations.
Brazil’s health regulator recently approved a locally produced version of the vaccine, a development the company described as a significant step forward for access in countries that need it most.
The Shigella vaccine program is also approaching a key milestone. Valneva is currently running two active studies: one involving children in Africa and another testing immune response and early protection through a controlled infection model at Johns Hopkins University.
Results from both are expected by mid-2026 and will shape the next chapter for a vaccine targeting a disease the World Health Organization has identified as the second leading cause of fatal diarrhea in children globally.
A lower outlook but reasons to stay the course
Valneva closed the first quarter with 105 million euros in cash and raised an additional 84 million euros through a capital offering completed in April, giving the company a meaningful financial buffer as it waits on key regulatory decisions. Its leadership has been clear that cost discipline is the priority for now, but the long-term strategy remains unchanged.
Two milestones will define the months ahead for Valneva: Pfizer’s planned regulatory filing for the Lyme vaccine and the forthcoming Shigella data readout. Together, they offer a counterweight to the financial pressures of restructuring and a reason to believe that the company’s most important chapter may still be ahead.
SOURCES: BENZINGA